Skip to main content
SpringerLink
Log in

Focus on biologicals at EULAR

  • Meeting report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Harrison M, Cummins C, Horneff G, Southwood T, Mines D.Cancer risk in juvenile arthritis patients exposed to etanercept: Results from three observational cohorts. 11th Annual Congress of the European League Against Rheumatism: abstr. OP0274, 16 Jun 2010. Available from: URL: http://www.eular.org

  2. McCroskery P, Wallace C, Lovell D, Stryker S, Chernyukhin N, Blosch C, Zack DJ.Summary of worldwide pediatric malignancies reported after exposure to etanercept. 11th Annual Congress of the European League Against Rheumatism: abstr. SAT0432, 16 Jun 2010. Available from: URL: http://www.eular.org

  3. Simard JF, Neovius M, Hagelberg S, Askling J.Juvenile Idiopathic Arthritis and Risk of Cancer: a Nationwide Cohort Study. 11th Annual Congress of the European League Against Rheumatism: abstr. OP0086, 16 Jun 2010. Available from: URL: http://www.eular.org

  4. Gottenberg J-E, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, Dougados M, Flipo R-M, Godeau B, Guillevin L, Hachulla E, Loet XL, Sibilia J, Schaeverbeke T, Baron G, Mariette X, French Socety of Rheumatology.Prospective follow-up of rituximab treatment in 2000 patients with refractory rheumatoid arthritis included in the air registry: risk factors of severe infections. 11th Annual Congress of the European League Against Rheumatism: abstr. OP0047, 16 Jun 2010. Available from: URL: http://www.eular.org

  5. Yazici Y, Swearingen C.Etanercept, Adalimumab and Abatacept Combination with Methotrexate Have Lower Odds Ratios of Discontinuations Due to Adverse Events and Serious Infections Compared to Infliximab and Methotrexate Combination: an Analysis of Rct Data. 11th Annual Congress of the European League Against Rheumatism: abstr. SAT0069, 16 Jun 2010. Available from: URL: http://www.eular.org

  6. Genovese M, Breedveld F, Emery P, Cohen S, Keystone E, Matteson E, Burke L, Chai A, Reiss W, Sweetser M, Shaw T.Rate of serious infections in RA patients who subsequently receive other biologic therapies after discontinuing rituximab treatment. 11th Annual Congress of the European League Against Rheumatism: abstr. OP0048, 16 Jun 2010. Available from: URL: http://www.eular.org

  7. Benucci M, Saviola G, Baiardi P, Manfredi M.Determinants of risk infection during therapy with anti TNF-alpha blocking agents in rheumatoid arthritis. 11th Annual Congress of the European League Against Rheumatism: abstr. AB0277, 16 Jun 2010. Available from: URL: http://www.eular.org

  8. Foeldvari I, Thome N, Horneff G.Methotrexate is protective against the new onset of uveitis under etanercept treatment: Data from the German etanercept registry. 11th Annual Congress of the European League Against Rheumatism: abstr. SAT0430, 16 Jun 2010. Available from: URL: http://www.eular.org

  9. Boteanu AL, Morales MP, Astete CAG, Lana MA, Pascual AR, Giraldo WAS, Pages FAA, Mendoza AZ, Cañamero MAB.Lipid profile modifications in patients receiving anti-TNF therapies due to systemic autoimmune diseases. 11th Annual Congress of the European League Against Rheumatism: abstr. AB0279, 16 Jun 2010. Available from: URL: http://www.eular.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Focus on biologicals at EULAR. React. Wkly. 1308, 4 (2010). https://doi.org/10.2165/00128415-201013080-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201013080-00008

Keywords

Search

Navigation